Peptides,
without the needle.
RHIVA was founded on a simple belief — that the most effective peptides in regenerative medicine should not require a syringe to deliver results. We built the formulation to bring clinical-grade copper peptide science to daily skincare, safely and consistently.
Injectable peptides
carry real risk.
GHK-Cu has been studied in regenerative medicine for over five decades. For years, the highest concentrations were delivered via injection — a method that is invasive, uncomfortable, expensive, and in many jurisdictions, unregulated. Self-administering peptide injections daily is not a sustainable or safe protocol for most people.
We asked a different question: what if we could engineer a topical delivery system precise enough to make injections unnecessary? The answer was the RHIVA microemulsion — an ultra-light, deep-penetrating carrier that delivers GHK-Cu at a clinically relevant 2% concentration, transdermally, without compromise.
One active.
Done properly.
Every RHIVA formula is built around a single efficacious active at a meaningful concentration. No padding, no filler, no compromise. We do not add an ingredient unless it earns its place through clinical evidence.
The GHK-Cu + Ectoin Microemulsion contains two actives — GHK-Cu at 2% for collagen synthesis and tissue remodelling, and Ectoin as a hydration shield that protects and stabilises the skin barrier during the regeneration process. Everything else in the formula exists only to deliver these two molecules to where they need to be.